Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Inclusion Criteria * Subjects were human immunodeficiency virus type 1 (HIV-1) positive, antiretroviral naïve adults at least 18 years of age with \< 7 days of prior antiretroviral therapy. * Subjects had plasma HIV-1 ribonucleic acid (RNA) levels \>= 1,000 copies/mL at screening and were not acutely ill. * Female subjects were nonpregnant and nonlactating. Exclusion Criteria * Subjects were excluded if screening laboratory analyses showed any of the following abnormal laboratory results: * Presence of hepatitis B surface antigen (HBsAg) * Hemoglobin \<= 8.0 g/dL * Absolute neutrophil count \<= 750 cells/microliter * Platelet count \<= 50,000 per mL * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>= 3.0 x Upper Limit of Normal (ULN) * Calculated creatinine clearance \< 50 mL/min